Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Patrys a leading ASX gainer on brain tumour trial breakthrough

Patrys Limited (ASX:PAB) surged to a 12-month high of $0.04 on news that its drug candidate PAT‐DX1 has been shown to reduce brain tumour size in animal trials. (1-0)

Patrys' shares halted

Patrys Ltd (ASX:PAB) has been granted a trading halt by the ASX this morning, pending details relating to managing its continuous disclosure obligations. (1-0)

Patrys wins another U.S. patent for its unique cancer antibody

Patrys Limited (ASX:PAB) has been granted a U.S. patent for its anti-cancer candidate PAT-LM1 for use in treating colon cancer metastasis. (1-0)

Patrys sits among Leading ASX % Gainers in afternoon trade

Patrys Ltd's (ASX:PAB) shares have jumped 42% to $0.027 on massive volume of over 100 million shares. (1-0)

Patrys is the ASX Most Traded, but losing momentum

Patrys Ltd (ASX:PAB) is the most active stock on the ASX today, trading 87 million shares by 2pm, but its losing yesterday's momentum in the share price.

Patrys takes another gong riding near the top of the ASX Most Active

Patrys Ltd's (ASX:PAB) shares have continued to rally during the trading day, and are now up 200% at $0.012, with over 84 million shares changing hands.

Patrys' positive pre-clinical data puts it on the podium of ASX Top % Gainers

Patrys Ltd's (ASX:PAB) shares are up 75% in morning trade at $0.007, following positive pre-clinical data for its lead drug candidate PAT-DX1, a novel first-in-class drug candidate being developed to treat a range of different cancers.

2015 AGM Presentation